Amarpreet Kaur Ahuja’s Post

Collaboration for a Healthier Future! AstraZeneca Pharma India Ltd and Mankind Pharma join forces to enhance access to vital asthma medication in India. Together, INDIA is making strides in healthcare. Stay tuned for more updates and photos from this exciting venture on our LinkedIn page! #pharmacollaboration #healthcareinnovation 

Collaboration for a Healthier Future! AstraZeneca Pharma India Ltd and Mankind Pharma join forces to enhance access to vital asthma medication in India. Together, INDIA is making strides in healthcare. Stay tuned for more updates and photos from this exciting venture on our LinkedIn page! #pharmacollaboration #healthcareinnovation

What’s meaningful to my work here at AstraZeneca? Beyond our dedication to advancing healthcare in Vietnam and ensuring equitable access to the latest and most effective treatments over our 30-year presence in the country, it is the meaningful collaboration and mutual trust we nurture with our stakeholders and partners that truly stand out. On September 30, 2024, I had the privilege of meeting with Vice Minister of the Ministry of Health, Mr. Do Xuan Tuyen, to discuss our ongoing and future contributions to Vietnam’s healthcare landscape. During this meeting, we outlined AstraZeneca Vietnam's key activities in: 💡Pharmaceutical Research and Development 💡Technology Transfer Projects aimed at producing advanced drugs locally. 💡Community Investment Programs aimed at creating an equitable and sustainable healthcare system, enhancing Vietnamese patients' access to advanced medications and treatments. We reaffirmed our alignment with Vietnam’s National Strategy for Pharmaceutical Industry Development and the National Program for Domestic Pharmaceutical Production by 2030, with a vision extending to 2045. Our goal is to support Vietnam in becoming a central hub for producing original brand-name drugs in the ASEAN region. Vice Minister Do Xuan Tuyen expressed high appreciation for AstraZeneca’s contributions and support over the years, particularly during the Covid-19 pandemic. He acknowledged our efforts in technology transfer, clinical trials, disease prevention and control, and our commitment to building a sustainable healthcare system. I felt both supported and encouraged after our discussion. With continued collaboration and support from the Ministry of Health, I am confident that we can achieve remarkable outcomes that benefit our people, society, and the planet. Picture below was taken with Vice Minister Do Xuan Tuyen in Hanoi. More information in Vietnamese: https://lnkd.in/gUH-auz3

Only put off until tomorrow what you are willing to die having left undone. ## AstraZeneca Beats Expectations with Q3 Core Earnings In an impressive display of resilience, AstraZeneca's third-quarter 2024 core earnings per American depositary share \(ADS\) came in at $1.04, surpassing the Zacks Consensus Estimate of $1.01 per share. Despite a year-over-year decline of 20% on a reported basis and 27% at constant exchange rates \(CER\), the company's core earnings of $2.08 per share demonstrate its ability to outperform under challenging circumstances. The pharmaceutical giant reported total revenues of $13.57 billion, representing an impressive 18% increase. This strong financial performance further highlights AstraZeneca's commitment to innovation and growth in the healthcare sector. With these promising results, investors have a unique opportunity to capitalize on the potential of AstraZeneca's future success. By investing in the company's shares, individuals can align their portfolios with the ever-evolving landscape of the healthcare industry. Don't miss out on this chance to grow your Health Savings Account and invest in the future of healthcare. Take action now to secure your financial well-being and ensure a brighter future for your family's health and wellness. #hsa #investing #healthcare #health #family #wellness 💼💰💊🚀💪😀📈

Sanofi's Strategic Move: Spinning Off Consumer Healthcare Division Valued at €20 Billion Sanofi is embarking on a significant strategic shift by spinning off its consumer healthcare division, a move that is anticipated to be valued at approximately €20 billion. Notably, this decision has been facilitated by reputable financial institutions such as Goldman Sachs and Morgan Stanley, aligning with a prevailing trend in the pharmaceutical industry. This trend involves the segregation of lower-margin consumer units from higher-margin pharmaceutical segments. CEO Paul Hudson is driving the company towards concentrating on research and development (R\&D) for rare diseases and immunology, despite a transient decline in Sanofi's shares following the announcement. The spin-off process is set to adopt a "dual track" approach, encompassing both a potential sale and a public listing, in a bid to optimize the expected outcomes. This strategic realignment is geared towards streamlining Sanofi's operations and intensifying its focus on innovative medicine. This move mirrors recent strategic endeavors by major players in the industry, such as GSK and Johnson & Johnson. # Thank you Fabienne Durand for your submission!

Centered around the theme Viksit Bharat @2047 — India's Path from the 'Pharmacy of the World' to the 'Pharma Powerhouse to the World', the summit set forth the vision for India's healthcare evolution. Organisation of Pharmaceutical Producers of India #healthcare #PharmaIndustrialIndia

🌍 Shaping the Future of Indian Pharma At the OPPI India Annual Summit 2024, industry leaders gathered to discuss transformative strategies for establishing India as a global pharmaceutical powerhouse. 💊 With insights on innovation, sustainability, and collaboration, the event underscored India's potential to lead in delivering affordable, high-quality healthcare solutions to the world. 📖 Dive deeper into the key takeaways and industry vision here: #PharmaLeadership #HealthcareInnovation #IndiaPharma #OPPI2024

Result of excellent leadership and commitment.

💡 Meanwhile, in major pharmaceutical news...What's the future of healthcare? 👩🔬 After launching several new, effective medicines and vaccines this year, Paul Hudson and his team at Sanofi have also received regulatory approval for a new treatment in lung disease. 🤖 Amongst these developments, they have also launched Modulus, a new type of AI powered factory that produces multiple vaccines and medicines at a faster rate which will only help the response time for future health crises. As Sanofi looks to focus on developing new medicines and treatments, they look to capitalize on becoming a pure-play biopharma organization by spinning off its consumer health business. 🔬 What does this mean for the industry...? - Innovation: They are leading the way in medicine manufacturing with AI, bringing a positive sign for the industry. - Patient Access: They are improving the health and well-being of millions as they strive for groundbreaking new treatments. - Industry Consolidation: Sanofi's decision to focus solely on biopharma could lead further organizations to specialize and focus on their core competencies. ⁉ What other impacts can you see Sanofi having on the industry? Is Big Biotech on the way? What are you most excited about in the future of healthcare? 🗯 Share your thoughts below! #HealthcareFuture, #Innovation, #PatientCentered

We finished Q3 strong, with broad-based, double-digit sales growth propelled by our launches of best-in-class medicines and vaccines.       The momentum of our Sanofi pipeline continues this quarter, with a sustained cadence of positive phase 3 data and major regulatory approvals, including three in a row - EU, US & China - for the first-ever biologic for certain adults with uncontrolled Chronic Obstructive Pulmonary Disease.      Our modernization is taking shape every day at an incredible pace. Last month, we inaugurated Modulus, the first AI-powered factory of the future. Modulus can manufacture up to four vaccines or biomedicines at a time, with the unique ability to quickly adapt in a matter of days in response to health challenges around the world. It’s one factory, but with infinite possibilities.      We’re also progressing with our strategy to create a focused player in Consumer Healthcare, giving Opella the opportunity to thrive as a global leader and paving the way for Sanofi to become a pure-play, science-driven biopharma company.       Looking to the future, I’m confident in the course we’ve charted and excited about what’s to come. Not only for Sanofi, but for the millions of people around the world who are counting on us.   Read more on our Q3 results here: https://lnkd.in/ejgVYWYN #SanofiResults #Science #Innovation